There was no appetite for specs as a whole on the ASX today...

There was no appetite for specs as a whole on the ASX today ahead of the EU meeting in Bruessels and the lack of monetary easing from Beijing.


The likelihood of a CR is diminishing as management would have taken the chance of an elevated shareprice.
The usual pump prior to a CR is missing, hence allowing one to speculate that partnering negotiations and favourable financing plans are in the making.


If ISIS is anything to go by in terms of setting the tone of how antisense technology is perceived Internationally, we should do well for ATL1103 and 1101 in the coming months.



ANP has lost the status of a trader's darling, this creates the chance for long to medium term holders to actively enlarge ones portfolio, reducing the percentages of short term holders and therefore exacerbating the move upwards once it runs again.

Phase 2 results for ATL1103 were partly anticipated during phase 1 trials, we are moving into the next stage with little downside regarding efficiacy of the drug.



Stay put and be rewarded accordingly within the next weeks as soon as management shares developments which are currently settled behind the scenes.